Compare Immunovant Inc. Common Stock (IMVT) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Schwab US Dividend Equity ETF trades at $33.12 (market cap $108.68B). The key difference: Schwab US Dividend Equity ETF is far larger — about 16.4× Immunovant Inc. Common Stock's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| IMVT | SCHD | |
|---|---|---|
Market Cap | $6.62B | $108.68B |
Volume | 1,131,364 | 21,463,071 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $35.21 |
52-Week Low | $17.03 | $26.44 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.
Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
